nach oben

Neurotoxicity Research

Erschienen in:

01.05.2014 | Original Article

Role of Nuclear Receptor on Regulation of BDNF and Neuroinflammation in Hippocampus of β-Amyloid Animal Model of Alzheimer’s Disease

verfasst von: Atish Prakash, Anil Kumar

Erschienen in: Neurotoxicity Research | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been reported to provide neuroprotective effects against neurodegenerative diseases. The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-γ agonist, on cognitive impairment in an animal model of Alzheimer’s disease induced by β-amyloid. Wistar rats received intracerebroventricular (ICV) β-amyloid (βA) application (3 nmol/3 μL), and behavioral alterations (locomotor activity and memory performance) were assessed. Animals were sacrificed immediately following the last behavioral session, and their brains were removed and dissected. Mitochondrial enzymes, oxidative parameters, inflammatory mediators (TNF-α, IL-6), caspase activity, and BDNF levels were measured in the hippocampus. ICV βA-treated rats showed a memory deficit and significantly decreased BDNF level, simultaneously, increase in mitochondrial oxidative damage and inflammatory mediators in the hippocampus. Memory impairment and oxidative damage were reversed by administration of pioglitazone (15 and 30 mg/kg). Pioglitazone also significantly restored the BDNF level and attenuated the actions of inflammatory markers in ICV βA-treated rats. However, pretreatment with PPAR-γ antagonist BADGE (15 mg/kg) with higher dose of pioglitazone significantly reversed its protective action in memory impairment in βA-treated rats, which indicates the involvement of PPAR-γ receptors mediating neuroprotective action. These results demonstrate that pioglitazone offers protection against β-amyloid-induced memory dysfunction possibly due to its antioxidant, anti-inflammatory, anti-apoptotic action and neurogenesis-like effect therefore, could have a therapeutic potential in Alzheimer’s disease.

Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, Dehpour AR (2011) Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 650:240–248PubMedCrossRef

Aoun P, Simpkins JW, Agarwal N (2003) Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci 44(7):2999–3004PubMedCrossRef

Arshavsky YI (2010) Why Alzheimer’s disease starts with memory impairment: neurophysiological insight. J Alzheimers Dis 20:5–16PubMed

Bishop-Bailey D (2009) Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Bystrom J Pharmacol Ther 124:141–150CrossRef

Brandolic Sanic A, De Bemardi MA (1998) BDNF and bFGF down regulate NMDA receptor function in cerebella anole cells. Neuroscience 18:7153–7161

Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24:10908–10917PubMedCrossRef

Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rizzuto R (2009) Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta 1787:335–344PubMedCentralPubMedCrossRef

Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M (1997) Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res 49(1–2):71–81PubMedCrossRef

d’Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, Azzi A, Marinari UM, Pronzato MA, Ricciarelli R (2005) Role of peroxisome proliferator-activated receptor-gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 391:693–698PubMedCentralPubMedCrossRef

Daynes RA, ones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2:748–759PubMedCrossRef

Diógenes MJ, Costenla AR, Lopes LV, Jerónimo-Santos A, Sousa VC, Fontinha BM, Ribeiro JA, Sebastião AM (2011) Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology 36:1823–1836PubMedCentralPubMedCrossRef

Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL (2010) Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75(6):500–507PubMedCentralPubMedCrossRef

Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77PubMedCrossRef

Ellman GL, Courtney V, Andres RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95PubMedCrossRef

Ferrer Krupinski J, Goutan E (2001) Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat. Acta Neuropathol 101:229–238PubMed

Fukui K, Takatsu H, Suzuki S, Abe K, Urano S (2005) Appearance of amyloid-like substances and delayed-type apoptosis in rat hippocampus CA1 region through aging and oxidative stress. J Alzheimer’s Dis 8(3):299–309

Gornall AG, Bardawill CT, David MM (1949) Determination of serum proteins by means of Biuret reaction. J Biol Chem 177:751–766PubMed

Green LC, Wagner DA, Glagowski J (1982) Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. J Biol Chem 193:265–275

Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O’Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPAR gamma agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice. Brain 128:1442–1453PubMedCrossRef

Heneka MT, Reyes-Irisarri E, Hüll M, Kummer MP (2011) Impact and therapeutic potential of PPARs in Alzheimer’s disease. Curr Neuropharmacol 9:643–650PubMedCentralPubMedCrossRef

Kaur B, Singh N, Jaggi AS (2009) Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol 23:557–566PubMedCrossRef

King TE (1967) Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol 10:322–331CrossRef

King TE, Howard RL (1967) Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 10:275–284CrossRef

Kono Y (1978) Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186:189–195PubMedCrossRef

Kumar A, Prakash A, Dogra S (2010) Naringin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress induced by d-galactose in mice. Food Chem Toxicol 48:626–632PubMedCrossRef

Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5(3):481–489PubMedCentralPubMedCrossRef

Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457:U1128–U1184CrossRef

Lee S, Fernandez EJ, Good TA (2007) Role of aggregation conditions in structure, stability, and toxicity of intermediates in the A beta fibril formation pathway. Protein Sci 16:723–732PubMedCentralPubMedCrossRef

Liu Y, Peterson DA, Kimura H, Schubert D (1997) Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochem 69:581–593PubMedCrossRef

Luck H (1971) Catalase. In: Bergmeyer HJ (ed) Methods of Enzymatic analysis, 3rd edn. Academic Press, New York, pp 885–893 vol. III

Mark RJ, Hensley K, Butterfield DA, Mattson MP (1995) Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca²⁺ homeostasis and cell death. J Neurosci 15:6239–6249PubMed

Maurice T, Lockhart BP, Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181–193PubMedCrossRef

Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R (2009) PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55:496–504PubMedCrossRef

Nicolakakis N, Hamel E (2010) The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer’s disease. Front Aging Neurosci 2:21PubMedCentralPubMedCrossRef

Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC (2011) Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychologia 49:2384–2390PubMedCrossRef

Prakash A, Kumar A (2009) Effect of N-acetyl cysteine against aluminium-induced cognitive dysfunction and oxidative damage in rats. Basic Clin Pharmacol Toxicol 105:98–104PubMedCrossRef

Prakash A, Kumar A (2013) Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model. Clin Exp Pharmacol Physiol 40(9):644–651PubMedCrossRef

Reddy PH, McWeeney S (2006) Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant mouse models. Neurobiol Aging 27(8):1060–1077PubMedCrossRef

Rial D, Piermartiri TC, Duarte FS, Tasca CI, Walz R, Prediger RD (2012) Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-β (Aβ(1-40)) administration in mice. Neuroscience 215:79–89PubMedCrossRef

Rozemuller AJ, Jansen C, Carrano A, van Haastert ES, Hondius D, van der Vies SM, Hoozemans JJ (2012) Neuroinflammation and common mechanism in Alzheimer’s disease and prion amyloidosis: amyloid-associated proteins, neuroinflammation and neurofibrillary degeneration. Neurodegener Dis 10:301–304PubMedCrossRef

Ruan CJ, Zhang L, Chen DH, Li Z, Du GH, Sun L (2010) Effects of trans-2,4-dimethoxystibene against the neurotoxicity induced by Abeta(25–35) both in vitro and in vivo. Neurosci Res 67(3):209–214PubMedCrossRef

Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23:9796–9804PubMed

Saxena G, Patro IK, Nath C (2011) ICV STZ induced impairment in memory and neuronal mitochondrial function: a protective role of nicotinic receptor. Behav Brain Res 224:50–57PubMedCrossRef

Siemers E (2011) Designing clinical trials for early (pre-dementia) Alzheimer’s disease: determining the appropriate population for treatment. J Nutr Health Aging 15(1):22–24PubMedCrossRef

Smith MA, Makino S, Kim SY, Kvetnansky R (1995) Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary. Endocrinology 136:3743–3750PubMed

Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A (1967) An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 32:415–438PubMedCentralPubMedCrossRef

Spuch C, Ortolano S, Navarro C (2012) New insights in the amyloid–beta interaction with mitochondria. J Aging Res 324968. doi:10.1155/2012/324968

Stéphan A, Phillips AG (2005) A case for a non-transgenic animal model of Alzheimer’s disease. Genes Brain Behav 4(3):157–172PubMedCrossRef

Storer PD, Xu J, Chavis J, Drew PD (2005) Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 161:113–122PubMedCrossRef

Sun H, Zhang J, Zhang L, Liu H, Zhu H, Yang Y (2010) Environmental enrichment influences BDNF and NR1 levels in the hippocampus and restores cognitive impairment in chronic cerebral hypoperfused rats. Curr Neurovasc Res 7:268–280PubMedCrossRef

Sundararajan S, Jiang Q, Heneka M, Landreth G (2006) PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 49(2):136–144PubMedCrossRef

Tam JH, Pasternak SH (2012) Amyloid and Alzheimer’s disease: inside and out. Can J Neurol Sci 39:286–298PubMed

Tanzi R, Bertram L (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120:545–555PubMedCrossRef

Tillement L, Lecanu L, Papadopoulos V (2011) Alzheimer’s disease: effects of β-amyloid on mitochondria. Mitochondrion 1:13–21CrossRef

Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H (2011) Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 89:1031–1042PubMedCrossRef

Wills ED (1966) Mechanism of lipid peroxide formation in animal tissues. Biochemical J 99:667–676

Zhang HY, Liu YH, Wang HQ, Xu JH, Hu HT (2008) Puerarin protects PC12 cells against beta-amyloid-induced cell injury. Cell Biol Int 32:1230–1237PubMedCrossRef

Titel: Role of Nuclear Receptor on Regulation of BDNF and Neuroinflammation in Hippocampus of β-Amyloid Animal Model of Alzheimer’s Disease
verfasst von: Atish Prakash
Anil Kumar
Publikationsdatum: 01.05.2014
Verlag: Springer US
Erschienen in: Neurotoxicity Research / Ausgabe 4/2014
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-013-9437-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

1MeTIQ Provides Protection Against Aβ-Induced Reduction of Surface Expression of Synaptic Proteins and Inhibits H2O2-Induced Oxidative Stress in Primary Hippocampal Neurons

Cisplatin Inhibits Hippocampal Cell Proliferation and Alters the Expression of Apoptotic Genes

Enhanced Mossy Fiber Sprouting and Synapse Formation in Organotypic Hippocampal Cultures Following Transient Domoic Acid Excitotoxicity

White Matter Injury Induced by Perinatal Exposure to Glutaric Acid

A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists